Lupus MSC Therapy Doubles Placebo Response in Phase II Trial
Image
Orlando – November 04, 2026 -- A single infusion of high-dose mesenchymal stromal cells (MSCs) produced treatment responses in nearly half of participants with refractory lupus, more than double the placebo rate, according to a Phase II trial funded by the Lupus Foundation of America (LFA). The results will be presented at the American College of Rheumatology (ACR) Convergence 2026 in Orlando, November 6-11.
MSC trial results support a confirmatory study
The multicenter, double-blind, placebo-controlled study (Abstract #LB17) will be presented by Dr. Gary Gilkeson on November 10. Its findings support further evaluation of high-dose MSCs in a confirmatory trial.